Diabetes Test from Verisana

At the displayed 99 USD with free shipping, the product combines a home collection kit, four related glycemic outputs, marker explanations, and a confidential digital report. Value is tempered by the fact that EAG is derived from HbA1c, the result timing is only a general estimate, assay and laboratory details are not product-specific, and the service is explicitly non-diagnostic. Customers may still need clinician-ordered confirmation or additional testing, and the displayed price can change under Verisana's terms. The score is assigned against the bounded declared question and the reviewed evidence.

The product discloses four glycemic outputs, but EAG is derived from HbA1c and therefore does not add a separate specimen measurement. NIDDK identifies fasting plasma glucose, oral glucose tolerance testing, and other clinical information as additional tools used in diabetes evaluation. The product page does not list those tests or broader renal, lipid, urine-albumin, medication, symptom, or clinical assessments, so coverage is useful for a narrow snapshot but limited for a complete diabetes evaluation. The score is assigned against the bounded declared question and the reviewed evidence.

Insulin, glucose, HbA1c, and EAG are directly relevant to a consumer question about glycemic status and blood-sugar monitoring. NIDDK explains that A1C reflects average glucose over about three months and that EAG is calculated from A1C, while the product page describes using the markers together. The set is relevant for a focused glycemic snapshot, but it cannot independently establish a diagnosis, explain every glucose abnormality, or replace clinical context and confirmatory testing.

The product promises a digital report with marker explanations and potential symptom information, provides secure-account delivery, and directs customers to discuss abnormal findings with a healthcare provider. Verisana FAQ says results do not include individualized therapy recommendations. The product page wording recorded in the prior evidence review describes HbA1c as six to eight weeks (the product page itself would not load for fresh re-verification on 2026-09-15); NIDDK guidance reviewed fresh the same day describes the A1C test as reflecting average blood glucose over the past three months, and that authoritative timeframe is adopted here, with the vendor wording read as an imprecise simplification. Interpretation is further limited because the product-specific reference intervals and report example are not public, and confirmation or follow-up pathways are not built into the service.

Verisana names four reported markers and provides a concrete dried-blood-spot collection workflow with a return card and a stated laboratory-analysis path. That supports a clear understanding of what the product intends to report. The public pages do not identify the product-specific performing laboratory, assay methods, instruments, calibration, analytical imprecision, interference testing, or validation data, and the product page's CLIA partner claim conflicts with the terms' statement that Verisana is not a CLIA-regulated clinical laboratory.

Online ordering, free standard US delivery, self-collected finger-prick sampling, supplied lancets and return materials, and digital results make the workflow practical for eligible customers. The kit normally arrives in 5 to 7 days, but registration is mandatory, the card must be filled and dried correctly, the sample-return instruction pairs a within-24-hours deadline with same-day drop-off guidance, which are compatible instructions (same-day drop-off satisfies the 24-hour deadline) rather than a genuine conflict, and the service excludes Puerto Rico, Maryland, New Jersey, New York, Rhode Island, and US territories according to the reviewed pages.

Verisana's product page promises sole-account access, sample disposal, and HIPAA-compliant portal and partner-lab handling. However, the privacy policy was last edited in November 2016, permits analytics, marketing, cookies, and third-party behavioral tracking, and provides broad retention language. The terms also allow transfer or processing outside the customer's country and assign sample and derived-information rights to Verisana and research or commercial partners. The conflicting assurances and dated policy support a cautious privacy score.

The official product page discloses the SKU, 99 USD price, free shipping, four named outputs, at-home collection, digital report, immediate kit availability, privacy claims, and state restrictions. The FAQ, delivery page, terms, and collection materials add order timing, result timing, registration, handling, and refund information. The terms state that Verisana Inc. itself does not constitute a clinical laboratory and is not subject to CLIA; this is compatible with the product page description of a CLIA-certified partner laboratory, because the company operates the service while the partner laboratory performs the testing, and the terms themselves distinguish the company from the laboratory that processes samples. Transparency is reduced by the lack of product-specific assay and reference-range documentation, the stale privacy-policy date, and the absence of a guaranteed result turnaround.